Since 1983, haematopoietic stem cell transplantation (HSCT) has been widely used to treat and cure many malignant and benign haematological diseases in Taiwan ([@bib6]). Although the overall survival after transplantation has gradually improved, important concerns remain regarding long-term complications of HSCT, such as secondary malignancy (SM), chronic graft-*vs*-host disease (cGVHD), infertility, and quality of life ([@bib15]). Recently, the development of SM has become a serious complication resulting in substantial mortality ([@bib27]).

Many studies conducted in Western countries have reported that HSCT increases the risk of SM, especially in patients receiving total body irradiation (TBI) or immunosuppressants and in patients with cGVHD ([@bib9], [@bib8]; [@bib21]; [@bib18]; [@bib19]). However, few studies have examined SM after HSCT in Asian populations. Moreover, the reported incidences and subtypes of secondary cancers are different from those reported in Western countries ([@bib23]; [@bib27]). To explore this issue in Taiwan, we conducted a nationwide population-based study using data from Taiwan\'s National Health Insurance (NHI) Research Database (NHIRD) to determine the incidence of SM after HSCT in the Taiwanese population.

Materials and methods
=====================

Data sources
------------

Taiwan\'s NHI is a mandatory universal health insurance programme that was established in 1995 to provide comprehensive medical care coverage for \>99% of Taiwanese residents ([@bib26]). The NHI covers prescription medications and outpatient, inpatient, emergency, and surgical services. The database includes enrollment files, prescription information, and coding for major procedures. This study is mainly based on data from the NHIRD, which is managed and publicly released by the National Health Research Institute (NHRI) of Taiwan.

In Taiwan, patients who receive HSCT or have malignant diseases are classified in the 'Catastrophic Illness\' group and maintained in a separate NHRI database (Catastrophic Illness Registry). Assignment to the Catastrophic Illness classification requires a definitive diagnosis based on pathological findings or clinical evidence that is widely accepted as sufficient to make a diagnosis. Confidentiality of data is managed and overseen by regulators of the Bureau of the NHI and the NHRI. This study was approved by the institutional review board of the Taipei Veterans General Hospital (2013-10-002CE).

Identification of patients receiving HSCT
-----------------------------------------

We conducted a retrospective cohort study from 1 January 1997 to 31 December 2010. We identified patients who received a first course of HSCT within the observation period based on the reimbursement for HSCT. To avoid confusion between primary malignancies treated by HSCT and SMs after HSCT, we only included patients receiving HSCT for haematologic malignancies, thalassaemia major, or severe aplastic anaemia. Patients receiving HSCT for solid organ cancers or immune deficiencies, metabolic disorders, or other congenital diseases were excluded. To avoid surveillance bias ([@bib3]; [@bib7]), patients who developed cancers within 1 year after HSCT, as well as those who were followed for \<1 year after HSCT were excluded. The following information was collected for all patients: basic data, comorbidities, primary diagnosis before HSCT, transplantation type (e.g., allogeneic HSCT (allo-HSCT) or autologous HSCT (auto-HSCT)), TBI, use of immunosuppressive agents, and cGVHD status. A diagnosis of cGVHD was made by an experienced haematologist who reviewed data regarding patterns of immunosuppressant use.

Statistical analyses
--------------------

The main dependent variable was the occurrence of solid organ cancers that were recorded in the Catastrophic Illness Registry. Patients were followed until the development of solid cancer, death, dropout from the NHI programme, or the end of 2011. Risk of SM in the HSCT cohort was calculated as the standardised incidence ratio (SIR), defined as the observed number of SM occurrence divided by the expected number of cases. The expected number was determined by multiplying the national incidence rate (in 5-year intervals) of same cancers stratified by gender, calendar year, and age, by the corresponding stratum-specific person-time accrued in this cohort. Incidence rates of cancers in the general population were obtained from the Taiwan Cancer Registry. The 95% confidence intervals (CIs) for the SIRs were estimated under the assumption that the number of cancers followed a Poisson probability distribution. We determined the SIRs for subgroups defined by age at HSCT, sex, follow-up time since HSCT, and stem cell type. In addition, the SIR was estimated for each SM subtype.

Physical comorbidities before HSCT, immunosuppressant use, and cGVHD development were analysed to determine hazard ratios for SM. Categorical variables were compared by Fisher\'s exact or chi-square tests. Continuous variables were compared with the Mann--Whitney *U*-test. Univariate and multivariate Cox proportional hazards models were utilised to identify predictors of SM in HSCT patients. All factors with a *P*-value of \<0.1 in the univariate analyses were included in the Cox multivariate analysis. Effects of immunosuppressant use after HSCT were treated as time-dependent variables to prevent an immortal time bias. Furthermore, if one type of immunosuppressant had a significant effect on SM in the Cox multivariate model, the effects of cumulative doses were estimated by time-dependent Cox proportional hazards models using cutoff points at non-use and the 50th percentile.

Data extraction and computations were performed with the Perl programming language (version 5.12.2; Perl Foundation, Walnut, CA, USA). Microsoft SQL Server 2005 (Microsoft Corp., Redmond, WA, USA) was used for data linkage, processing, and sampling. All statistical analyses were performed with the SAS 9.2 software (SAS Institute Inc., Cary, NC, USA). Statistical significance was defined as a *P*-value of \<0.05.

Results
=======

Clinical characteristics of the study population
------------------------------------------------

A total of 4014 patients who received HSCT between 1997 and 2010 were identified. After excluding patients who were treated with HSCT for metabolic disorders, severe combined immunodeficiency, or solid cancers (*n*=230), who had solid cancer before HSCT (*n*=112), who had \<1 year of follow-up (*n*=1122), and who developed secondary solid cancer within 1 year after HSCT (*n*=6), a total of 2544 patients met eligibility criteria and were enrolled in the study ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Patient demographics are detailed in [Table 1](#tbl1){ref-type="table"}. Study subjects were predominantly male (56.6%) and had a median age of 32 years (interquartile range, 20--45 years). Chronic obstructive pulmonary disease (COPD; 12.2%), dyslipidemia (12.1%), diabetes mellitus (10.4%), and chronic kidney disease (10.0%) were the most common comorbidities.

Risk of secondary malignancy according to age, sex, and time interval after transplantation
-------------------------------------------------------------------------------------------

A total of 43 SM occurred within the observation period ([Tables 2A and B](#tbl2A){ref-type="table"}). The incidence of SM in those receiving HSCT was higher than the incidence of cancers in the general population (SIR 2.00, 95% CI 1.45--2.69; *P*\<0.001). Concerning the stem cell type, incidence of cancers in patients receiving allogeneic HSCT was higher than in the normal population (SIR 2.77, 95% CI 1.81--4.05; *P*\<0.001). The increases were observed in both male (SIR 2.82, 95% CI 1.54--4.73; *P*=0.001) and female patients (SIR 2.71, 95% CI 1.40--4.73; *P=*0.004). In patients who received auto-HSCT, however, only males had a higher SIR of SM compared with the general population (SIR 1.89, 95% CI 1.03--3.17; *P*=0.040).

In the sub-analysis by age, the risks of SM were greater for younger patients. For example, those aged 0--19 years after either allo-HSCT (SIR 15.24, 95% CI 1.85--55.07; *P*=0.016) or auto-HSCT (SIR 49.91, 95% CI 1.26--278.07; *P*=0.040) had higher risk of SM compared with patients over 60 years who received allo-HSCT (SIR 2.30, 95% CI 0.28--8.30; *P*=0.433) or auto-HSCT (SIR 1.68, 95% CI 0.55--3.92; *P*=0.359). Regarding follow-up time after transplantation, the risk of SM increased nearly four-fold for patients who were followed for 5--10 years after allo-HSCT (SIR=4.56; 95% CI=2.55--7.53; *P*\<0.001) ([Table 2A](#tbl2A){ref-type="table"}). The cumulative incidence rate of overall SM after HSCT is 0.75% (95% CI=0.42--1.34%) in 5 years and 4.11% (95% CI=2.82--5.96%) in 10 years. The detailed results are outlined in [Figure 1](#fig1){ref-type="fig"}.

Specific subtypes of cancers
----------------------------

Among the 26 malignancies that occurred after allo-HSCT, the most commonly observed cancers originated in the head and neck (*n*=14), the digestive tract (*n*=8), and the lung or mediastinum (*n*=3). Compared with the general population, patients who received allo-HSCT had significantly higher SIRs for neoplasms of the oesophagus (SIR 14.75, 95% CI 4.02--37.76; *P\<*0.001) and the oral cavity (SIR 14.18, 95% CI 7.55--24.25; *P*\<0.001). Regarding gender, women with allo-HSCT were at greater risk of liver and biliary tract malignancies (SIR 17.31, 95% CI 3.57--50.58; *P=*0.001), but this risk was not observed in male patients. Although there was an increased incidence of SM in males receiving auto-HSCT, they did not appear to be at greater risk for any specific cancer subtypes. Results of these analyses are detailed further in [Table 3](#tbl3){ref-type="table"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Predictors of cancer risk
-------------------------

According to the univariate Cox proportional hazards analysis, the following characteristics increased the risk of SM after allo-HSCT: age ⩾40 years, HSCT for malignant disease, COPD, cGVHD, and use of the immunosuppressants sirolimus and azathioprine ([Table 4](#tbl4){ref-type="table"}). In the multivariate Cox proportional hazards analysis, azathioprine use (HR 2.55, 95% CI 1.13--5.77; *P*=0.025) was the only significant risk factor. There were trends for cGVHD (HR 2.19, 95% CI 0.91--5.27; *P*=0.082) and sirolimus use (HR 6.34, 95% CI 0.81--49.29; *P*=0.078) to be risk factors.

Time-dependent Cox proportional hazard models adjusted for the variables listed in [Table 5](#tbl5){ref-type="table"} were performed to analyse the relationship between azathioprine dose and SM. Using the 50th percentile of cumulative doses as the cutoff point, a cumulative azathioprine dose of \>15 100 mg after HSCT significantly increased the risk of SM. Exposure ⩾15 100 mg would induce significantly higher risk (HR 3.58, 95% CI 1.37--9.38; *P*=0.01) than those with \<15 100 mg (HR 2.51, 95% CI 0.90--6.99; *P*=0.079) in comparison with non-use ones ([Table 5](#tbl5){ref-type="table"}). Regarding auto-HSCT, patients who were 40 years or older, male, or had COPD had higher hazard ratios in the univariate analysis ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}), but only age ⩾40 years was significant for inclusion in the multivariate analysis (HR 3.74, 95% CI 1.19--11.80; *P*=0.024).

Receiving TBI as part of the conditioning regimen did not increase the risk of SM (HR 0.95, 95% CI 0.41--2.18; *P*=0.897) in the univariate analysis of allo-HSCT patients. An analysis tried to explore the association between TBI or cGVHD and various subtypes of SM revealed no association between TBI and any cancer subtype ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}), but cGVHD was a significant risk factor for head and neck cancer (HR 2.84, 95% CI 1.02--7.92; *P*=0.046) ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}).

Discussion
==========

This nationwide population-based study showed that a cohort of 2544 adult patients who received HSCT had an ∼2-fold greater risk of SM compared with the general population. The most common SMs were cancers of the oral cavity and oesophagus in both men and women who received allo-HSCT. The single greatest risk factor for development of SM after allo-HSCT was azathioprine use, which increased the risk of cancer in a dose-dependent manner. Although patients under 19 years of age had the highest SIR, patients 40 years or older were at greater risk for developing SM after auto-HSCT.

In Taiwan, both HSCT and cancer are classified under the 'Catastrophic Illness\' category by the NHI due to their large associated costs. The NHI has implemented an extremely strict verification process before issuing certification for treatment and requires pathological proof of malignancy or a clinical diagnosis based on laboratory and imaging evidence. Therefore, the diagnosis of malignancies should be accurate and not over- or under-estimated. In addition, the NHI defines clear and strict indications for HSCT, as an expensive procedure. Peer review of cases is required to ensure that patient criteria are met. Thus, the diagnoses are reliable and precise.

Several published studies reported an increased risk of developing SM after HSCT ([@bib9]; [@bib21]; [@bib27]). The risk ratio differs between studies. [@bib9] reported the risk to be as high as 8.3 times the expected incidence in those surviving \>10 years after transplantation. A recent study of data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the Fred Hutchinson Cancer Research Center (FHCRC) database demonstrated that patients developed solid cancers after transplantation at twice the rate expected in the general population ([@bib21]). These results are similar to our findings and those reported by [@bib27] in Japan. Of note, the SIR of SM was higher in young patients and increased with time. [@bib21] reported competing risk analyses were 1% (95% CI 0.9--1.3%) at 10 years, 2.2% (95% CI 1.7--2.7%) at 15 years, and 3.3% (95% CI 2.4--4.5%) at 20 years after HSCT. Our study also found that the SIR of cancer development after HSCT increased with longer follow-up times.

It is well known that use of immunosuppressants increases the risk of developing a secondary malignancy. Combination use of steroids, azathioprine, and cyclosporine significantly increased the risk of skin cancer after renal transplantation ([@bib4]). In HSCT, both chronic inflammation from cGVHD and immunosuppressant use may predispose patients to developing secondary malignancies. In 1996, an analysis of 700 patients undergoing HSCT for aplastic anaemia and Fanconi anaemia revealed that azathioprine for cGVHD was a definite risk for solid tumour development after allo-HSCT ([@bib10]). Another international case--control study identified several major risk factors for the development of squamous cell carcinoma after HSCT, including prolonged azathioprine use, especially when it was combined with cyclosporine and steroids for severe cGVHD ([@bib8]). The risk ratio was 8.44 (95% CI 3.17--22.47; *P*\<0.001) in patients receiving cGVHD therapy for \>24 months. An analysis of different immunosuppressants and therapy duration found that azathioprine, cyclosporine, and steroid therapy for \>12 months, with or without other therapies, increased the risk of squamous cell carcinoma 38 times ([@bib8]). However, this study did not mention any association between azathioprine dose and SM.

In our study, a total of 128 patients have been treated with azathioprine in the 751 documented cGVHD patients, and it demonstrated that azathioprine increased SM risk by two-fold, and the risk increased with higher cumulative doses. This finding suggests that not only duration, but also the cumulative dose of azathioprine affects the risk of SM after allo-HSCT. Azathioprine is an oral immunosuppressant that requires metabolic activation into thioguanine nucleotides. These nucleotide analogues (specifically, 6-thioguanine (6-TG)) are incorporated into DNA. DNA containing 6-TG, especially after radiation therapy, is susceptible to mutagenic oxidation and carries a risk of therapy-related cancer in long-term survivors of transplantation ([@bib20]).

Regarding the cancer subtypes of patients with allo-HSCT, the most common SMs are oral cavity tumours ([@bib8]; [@bib13]; [@bib21]; [@bib19]). However, there are some epidemiological differences between Western and Eastern countries. Reports of data from the CIBMTR and FHCRC, which encompass populations in the United States of America and European countries, demonstrated that the sites of SMs, in order of decreasing incidence, were as follows: the oral cavity, liver, brain and central nervous system, and thyroid ([@bib24]; [@bib21]). However, our study from Taiwan and another from Japan ([@bib27]) revealed that in addition to cancers of the oral cavity, oesophageal cancer is also a common SM following allo-HSCT ([@bib13]; [@bib23]; [@bib5]). This difference may be related to the higher incidence of oesophageal cancer in Asian countries ([@bib25]; [@bib17]; [@bib28]). Another notable difference is skin cancer, which is more frequent in Western countries and usually presents as melanoma rather than squamous or basal cell carcinoma. Skin cancer with melanoma was reported as an excess absolute risk of 1.5 by the CIBMTR and the FHCRC ([@bib21]), but squamous or basal cell carcinoma is more common in Asian countries ([@bib13]; [@bib27]).Our study and the one by [@bib23] reported that no skin cancer was observed after allo- or auto-HSCT.

Use of TBI in HSCT has been described as a major risk factor for SM ([@bib8]; [@bib12]). However, our study and others showed no significant association between SM and radiation therapy ([@bib13]; [@bib23]; [@bib27]). One explanation for this discrepancy is the smaller proportion of young patients and shorter follow-up time after HSCT in our study. However, other pediatric studies and studies with long follow-up periods also found no association between SM and age or TBI ([@bib2]; [@bib14]). Similarly, TBI is associated with increased risk of skin cancers, such as melanoma ([@bib21]) and basal or squamous cell carcinoma ([@bib16]; [@bib22]), but as mentioned above, no skin cancer was observed in our study or a study in Japan ([@bib23]). This discrepancy requires further investigation and may be the result of ethnic differences.

Another significant risk factor for SM in other studies is cGVHD ([@bib8]; [@bib21]; [@bib18]; [@bib19]).While cGVHD had a hazard ratio of 2.19 for SM in our study, it was not significant in the multivariate analysis. The lack of statistical significance could be due to small patient number, however, the statistical trend may still implicate cGVHD as an independent risk factor for SM. There were 751 cases of cGVHD in our 1514 patients. This incidence of cGVHD was ∼49%, which is higher than in reports from Western countries ([@bib21]; [@bib19]) and another Taiwanese study ([@bib1]). Additional evidence comes from the significant effects of immunosuppressant use. The demand for prolonged use of immunosuppressants reflects the severity and duration of cGVHD. It is possible that in addition to immunosuppressants being a risk factor, cGVHD is, independently or synergistically with immunosuppressants, a risk factor for SM. A previous study also showed that cGVHD and the use of immunosuppressants are independent risks and the occurrence of both factors contributed to higher cancer risk ([@bib8]). Finally, patients had a much greater risk of SM following allo-HSCT than auto-HSCT, which had only slight increase of risk in male patients. This observation suggests that, in addition to high-dose chemotherapy-induced DNA damage, immunosuppressants (especially azathioprine) and cGVHD are important risk factors for SM.

Our study is limited as a retrospective analysis and NHI database. We were unable to obtain detailed information about severity grading of cGVHD, stage of primary disease, and donor--recipient relationships. However, a multivariate analysis of the CIBMTR database conducted by [@bib9] revealed that HLA type or familial relationships did not increase the risk of SM ([@bib21]). No information about conditioning regimen was available in our study, but a previous study reported that it did not influence the risk of SM development ([@bib13]). [@bib19] reported that conditioning with busulfan-cyclophosphamide increased SM in the oral cavity and other cancers, but that study only focused on busulfan-cyclophosphamide and not on other regimens. The association between the conditioning regimen and SM is still inconclusive and requires more investigation. Many other potential risk factors, such as T-cell depletion and manipulation, anti-thymocyte globulin, and lifestyle characteristics such as smoking or alcohol use, were not available for our analysis. However, these factors did not affect SM development in several previous studies ([@bib9], [@bib8]; [@bib13]; [@bib21]).

In conclusion, patients receiving HSCT have approximately twice the risk of developing SM than the general population, and this risk increases with time. The incidence of oral and oesophageal cancers in Taiwanese patients significantly increases after allo-HSCT. This result is a unique clinical feature that is different from patients in Western countries, where the oesophageal cancer risk is not increased. The use of the immunosuppressant azathioprine, especially with cumulative doses exceeding 15 100 mg, increases the risk of SM. Taking the autologous transplantation as a reference, our study demonstrates the significant effects of cGVHD and immunosuppressants as the risk of SM. Physicians should be cautious when using azathioprine for GVHD after HSCT. This study suggests that long-term survivors who are treated with HSCT, especially those with risks mentioned above, should be kept under long-term surveillance for early detection of SM.
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###### Characteristics of patients with haematopoietic stem cell transplantation (HSCT)

                                                          **Total**           **Male**           **Female**
  -------------------------------------------------- ------------------- ------------------- -------------------
  No. of patients                                           2544                1439                1105
  Person-years at risk                                     11 198              6075.6              5122.8
  Median follow-up, years (interquartile range)       4.46 (2.11--7.75)   4.21 (2.00--7.65)   4.82 (2.31--8.05)
  Median age, years (interquartile range)                32 (20--45)         32 (20--45)         33 (20--46)
  **Primary disease**                                                                        
  Acute lymphoblastic leukaemia                          293 (11.5%)         167 (11.6%)         126 (11.4%)
  Acute myeloid leukaemia                                867 (34.2%)         458 (31.8%)         409 (37.0%)
  Lymphoma                                               678 (26.6%)         390 (27.1%)         288 (26.0%)
  Multiple myeloma                                       270 (10.6%)         172 (12.0%)          98 (8.9%)
  Severe aplastic anaemia                                270 (10.6%)         162 (11.3%)         108 (9.9%)
  Thalassaemia                                            68 (2.7%)           30 (2.1%)           38 (3.4%)
  Others[a](#t1-fn2){ref-type="fn"}                       98 (3.8%)           60 (4.1%)           38 (3.4%)
  **Treatment**                                                                              
  TBI                                                    605 (23.8%)         335 (23.3%)         270 (24.4%)
  Pre-HSCT Radiotherapy                                  841 (33.1%)         469 (32.6%)         372 (33.7%)
  Allogeneic                                            1514 (59.5%)         836 (58.1%)         678 (61.3%)
  Autologous                                            1030 (40.5%)         603 (41.9%)         427 (38.7%)
  cGVHD                                                  751 (49.6%)         413 (49.4%)         338 (49.8%)
  **Immunosupressants**[b](#t1-fn3){ref-type="fn"}                                           
  Cyclosporin                                           1471 (97.1%)         805 (96.2%)         666 (98.2%)
  Tacrolimus                                             138 (9.1%)           76 (9.1%)           62 (9.1%)
  Methylprednisolone                                     253 (16.7%)         134 (16.0%)         119 (17.5%)
  Mycophenolate                                          253 (16.7%)         145 (17.3%)         108 (15.9%)
  Sirolimus                                               36 (2.3%)           24 (2.8%)           12 (1.7%)
  Anti-thymocyte globulin                                381 (25.1%)         207 (24.7%)         174 (25.6%)
  Azathioprine                                           254 (16.7%)         153 (18.3%)         101 (14.8%)
  Cyclophosphamide                                        31 (2.0%)           16 (1.9%)           15 (2.2%)
  Methotrexate                                            41 (2.7%)           23 (2.7%)           18 (2.6%)
  **Comorbidities**                                                                          
  Diabetes mellitus                                      265 (10.4%)         162 (11.3%)         103 (9.3%)
  COPD                                                   311 (12.2%)         195 (13.6%)         116 (10.5%)
  Chronic kidney disease                                 255 (10.0%)         159 (11.0%)          96 (8.7%)
  Liver cirrhosis                                         48 (1.9%)           27 (1.9%)           21 (1.9%)
  Autoimmune diseases                                    152 (6.0%)           67 (4.7%)           85 (7.7%)
  Dyslipidaemia                                          309 (12.1%)         135 (9.4%)          174 (15.7%)
  **Age at HSCT, years**                                                                     
  0--19                                                  545 (21.4%)         302 (21.0%)         243 (22.0%)
  20--39                                                1027 (40.4%)         567 (39.4%)         460 (41.6%)
  40--59                                                 871 (34.2%)         508 (35.3%)         363 (32.9%)
  ⩾60                                                    101 (4.0%)           62 (4.3%)           39 (3.5%)

Abbreviations: cGVHD=chronic graft *vs* host disease; COPD=chronic obstructive pulmonary disease; TBI=total body irradiation.

Others: chronic lymphoid leukaemia; chronic myeloid leukaemia; myelodysplastic syndrome.

Immunosupressants are only indicated in allo-HSCT.

###### Standardised incidence ratios according to sex, age at HSCT, and follow-up time since allogeneic HSCT

                                  **Total**   **Male**   **Female**                                                                                          
  ------------------------------- ----------- ---------- ------------ --------------------- ---- ------ -------- ---------------------- ---- ------ -------- --------------------
  All cancers                     26          9.40       6998.7       2.77 (1.81--4.05)     14   4.97   3704.3   2.82 (1.54--4.73)      12   4.43   3294.4   2.71 (1.40--4.73)
  **Age at HSCT, years**                                                                                                                                     
  0--19                           2           0.13       1691.0       15.24 (1.85--55.07)   2    0.06   832.0    30.84 (3.73--111.39)   0    0.07   859.0    0.00 (0.00--55.61)
  20--39                          9           2.00       3353.4       4.51 (2.06--8.56)     4    0.89   1816.8   4.49 (1.22--11.49)     5    1.10   1536.7   4.53 (1.47--10.56)
  40--59                          13          6.39       1868.0       2.03 (1.08--3.48)     7    3.28   992.4    2.13 (0.86--4.39)      6    3.11   875.6    1.93 (0.71--4.20)
  ⩾60                             2           0.87       86.3         2.30 (0.28--8.30)     1    0.72   63.1     1.39 (0.04--7.74)      1    0.15   23.2     6.67 (0.17--37.14)
  **Follow-up time since HSCT**                                                                                                                              
  1--5                            4           4.99       4078.4       0.80 (0.22--2.05)     3    2.60   2182.3   1.15 (0.24--3.37)      1    2.38   1896.1   0.42 (0.01--2.34)
  5--10                           15          3.29       2315.3       4.56 (2.55--7.53)     8    1.74   1206.6   4.59 (1.98--9.04)      7    1.54   1108.7   4.54 (1.82--9.34)
  ⩾10                             7           1.12       605.1        6.23 (2.50--12.84)    3    0.62   315.4    4.84 (1.00--14.13)     4    0.50   289.6    7.95 (2.17--20.35)

Abbreviations: CI=confidence interval; HSCT=haematopoietic stem cell transplantation; SIR=standardised incidence ratio.

###### Standardised incidence ratios according to sex, age at HSCT, and follow-up time since autologous HSCT

                                  **Total**   **Male**   **Female**                                                                                          
  ------------------------------- ----------- ---------- ------------ ---------------------- ---- ------ -------- ---------------------- --- ------ -------- ---------------------
  All cancers                     17          12.12      4199.6       1.40 (0.82--2.25)      14   7.41   2371.3   1.89 (1.03--3.17)      3   4.71   1828.4   0.64 (0.13--1.86)
  **Age at HSCT, years**                                                                                                                                     
   0--19                          1           0.02       226.4        49.91 (1.26--278.07)   1    0.01   133.3    89.66 (2.27--499.54)   0   0.01   93.1     0.00 (0.00--415.27)
   20--39                         1           1.02       1591.7       0.98 (0.02--5.47)      1    0.44   821.5    2.29 (0.06--12.74)     0   0.58   770.2    0.00 (0.00--6.35)
   40--59                         10          8.11       2052.3       1.23 (0.59--2.27)      9    4.89   1219.2   1.84 (0.84--3.49)      1   3.22   833.1    0.31 (0.01--1.73)
   ⩾60                            5           2.97       329.2        1.68 (0.55--3.92)      3    2.07   197.2    1.45 (0.30--4.23)      2   0.90   132.0    2.22 (0.27--8.01)
  **Follow-up time since HSCT**                                                                                                                              
   1--5                           7           7.74       2667.6       0.90 (0.36--1.86)      4    4.78   1523.8   0.84 (0.23--2.14)      3   2.96   1143.8   1.01 (0.21--2.97)
   5--10                          7           3.45       1252.4       2.03 (0.82--4.18)      7    2.08   701.1    3.36 (1.35--6.93)      0   1.37   551.3    0.00 (0.00--2.69)
   ⩾10                            3           0.94       279.6        3.19 (0.66--9.32)      3    0.55   146.4    5.43 (1.12--15.86)     0   0.39   133.2    0.00 (0.00--9.52)

Abbreviations: CI=confidence interval; HSCT=haematopoietic stem cell transplantation; SIR=standardised incidence ratio.

###### Standardised incidence ratios for secondary cancer subtypes among patients with allogeneic HSCT

                             **Total**   **Male**   **Female**                                                          
  -------------------------- ----------- ---------- --------------------- ---- ------ --------------------- ---- ------ -----------------------
  All cancers                26          9.40       2.77 (1.81--4.05)     14   4.97   2.82 (1.54--4.73)     12   4.43   2.71 (1.40--4.73)
  Head and neck              14          1.65       8.46 (4.63--14.20)    9    1.47   6.11 (2.79--11.60)    5    0.18   27.59 (8.96--64.37)
   Oral cavity               13          0.92       14.18 (7.55--24.25)   8    0.85   9.44 (4.08--18.61)    5    0.07   71.94 (23.36--167.88)
   Pharynx and others        1           0.74       1.36 (0.03--7.55)     1    0.63   1.60 (0.04--8.90)     0    0.11   0.00 (0.00--33.01)
  Digestive                  8           2.88       2.78 (1.20--5.47)     3    2.14   1.40 (0.29--4.09)     5    0.74   6.78 (2.20--15.82)
   Oesophagus                4           0.27       14.75 (4.02--37.76)   3    0.26   11.44 (2.36--33.42)   1    0.01   112.31 (2.84--625.78)
   Stomach                   0           0.31       0.00 (0.00--12.01)    0    0.19   0.00 (0.00--19.21)    0    0.12   0.00 (0.00--32.07)
   Colon and rectum, Anus    1           1.05       0.95 (0.02--5.32)     0    0.64   0.00 (0.00--5.74)     1    0.40   2.47 (0.06--13.76)
   Liver and biliary tract   3           1.15       2.62 (0.54--7.64)     0    0.97   0.00 (0.00--3.79)     3    0.17   17.31 (3.57--50.58)
   Pancreas                  0           0.11       0.00 (0.00--34.43)    0    0.07   0.00 (0.00--51.50)    0    0.04   0.00 (0.00--103.82)
  Lung and mediastinum       3           0.70       4.26 (0.88--12.44)    1    0.44   2.26 (0.06--12.58)    2    0.26   7.64 (0.93--27.61)
  Bone and Soft tissue       0           0.15       0.00 (0.00--24.05)    0    0.09   0.00 (0.00--40.57)    0    0.06   0.00 (0.00--59.07)
  Skin                       0           0.12       0.00 (0.00--29.51)    0    0.08   0.00 (0.00--48.96)    0    0.05   0.00 (0.00--74.30)
  Breast                     0           1.71       0.00 (0.00--2.16)     0    0.00   0.00 (0.00--752.49)   0    1.70   0.00 (0.00--2.17)
  Genitourinary              0           1.31       0.00 (0.00--2.82)     0    0.40   0.00 (0.00--9.28)     0    0.91   0.00 (0.00--4.04)
  Thyroid                    0           0.52       0.00 (0.00--7.04)     0    0.12   0.00 (0.00--31.75)    0    0.41   0.00 (0.00--9.04)
  All others                 1           0.34       2.95 (0.07--16.46)    1    0.22   4.50 (0.11--25.10)    0    0.12   0.00 (0.00--31.66)

Abbreviations: CI=confidence interval; HSCT=haematopoietic stem cell transplantation; SIR=standardised incidence ratio.

###### Risk factors for secondary cancer development in patients with allogeneic HSCT

                                                     **Univariate analysis**       **Multivariate analysis**[a](#t4-fn2){ref-type="fn"}                        
  -------------------------------------------------- ----------------------------- ------------------------------------------------------ -------------------- -------
  Age ⩾40                                            2.79 (1.24--6.27)             0.013                                                  2.06 (0.85--4.97)    0.109
  Sex (male)                                         1.04 (0.48--2.24)             0.931                                                  0.91 (0.42--1.99)    0.819
  **HSCT**                                                                                                                                                     
  Malignancies vs. benign                            3.10 (0.93--10.32)            0.066                                                  2.32 (0.68--7.88)    0.178
  PBSCT *vs* BMSCT                                   1.83 (0.53--6.29)             0.339                                                                        
  **Comorbidities**                                                                                                                                            
  Diabetes mellitus                                  0.93 (0.13--6.86)             0.940                                                                        
  COPD                                               3.23 (1.10--9.48)             0.033                                                  2.41 (0.78--7.40)    0.126
  Chronic kidney disease                             0.73 (0.10--5.41)             0.756                                                                        
  Liver cirrhosis                                    [b](#t4-fn3){ref-type="fn"}   0.989                                                                        
  Autoimmune diseases                                0.98 (0.13--7.28)             0.987                                                                        
  Dyslipidaemia                                      2.73 (0.81--9.27)             0.107                                                                        
  cGVHD                                              2.31 (0.97--5.51)             0.058                                                  2.19 (0.91--5.27)    0.082
  **Treatment**                                                                                                                                                
  TBI                                                0.95 (0.41--2.18)             0.897                                                                        
  Pre-HSCT radiotherapy                              0.85 (0.38--1.90)             0.683                                                                        
  **Immunosuppressant**[c](#t4-fn4){ref-type="fn"}                                                                                                             
  Cyclosporin                                        [b](#t4-fn3){ref-type="fn"}   0.991                                                                        
  Tacrolimus                                         2.35 (0.70--7.89)             0.166                                                                        
  Methylprednisolone                                 1.48 (0.62--3.53)             0.373                                                                        
  Mycophenolate                                      0.71 (0.17--3.01)             0.642                                                                        
  Sirolimus                                          5.57 (0.74--41.80)            0.095                                                  6.34 (0.81--49.29)   0.078
  Anti-thymocyte globulin                            0.40 (0.05--2.96)             0.367                                                                        
  Azathioprine                                       3.14 (1.44--6.88)             0.004                                                  2.55 (1.13--5.77)    0.025
  Cyclophosphamide                                   1.13 (0.34--3.79)             0.841                                                                        
  Methotrexate                                       1.05 (0.36--3.07)             0.926                                                                        

Abbreviations: BMSCT=bone marrow stem cell transplantation; cGVHD=chronic graft *vs* host disease; CI=confidence interval; COPD=chronic obstructive pulmonary disease; HSCT=haematopoietic stem cell transplantation; HR=hazard ratio; PBSCT=peripheral blood stem cell transplantation; TBI: total body irradiation.

All factors with *P*\<0.1 in univariate analyses and sex were included in the Cox multivariate analysis.

Do not converge.

Immunosuppressant was analysed as a time-dependent covariate in the Cox regression model.

###### Cumulative dose of azathioprine for secondary cancer development in patients with allogeneic HSCT

                                                **Univariate analysis**   **Multivariate analysis**[a](#t5-fn2){ref-type="fn"}                       
  --------------------------------------------- ------------------------- ------------------------------------------------------ ------------------- -------
  **Azathioprine**[b](#t5-fn3){ref-type="fn"}                                                                                                        
  Non-use                                       Reference                                                                        Reference            
   \<15 100 mg                                  2.67 (0.96--7.40)         0.060                                                  2.51 (0.90--6.99)   0.079
   ⩾15 100 mg                                   3.68 (1.42--9.51)         0.007                                                  3.58 (1.37--9.38)   0.010
   Dose--response  relationship                 1.97 (1.26--3.09)         0.003                                                  1.94 (1.22--3.07)   0.005

Abbreviations: CI=confidence interval; HSCT=haematopoietic stem cell transplantation; HR=hazard ratio.

Azathioprine was analysed as a time-dependent covariate in the Cox regression model and adjusted with variables listed in [Table 4](#tbl4){ref-type="table"} multivariate analysis.

With cutoff points at non-use and the 50th percentile of cumulative dose.

[^1]: J-P Gau and C-J Liu share co-corresponding authorship.
